(5) Special populations benefit from tailored approaches, e.g., MHT until age 51 for POI, non-hormonals for cancer survivors, and GLP-1 agonists with MHT for metabolic conditions, addressing disparities via pharmacogenomics (10, 11, 17, 23, 38). This evidence concerns the gene GLP1R and cancer.